Skip to main content
. Author manuscript; available in PMC: 2022 Mar 15.
Published in final edited form as: J Immunol. 2021 Jan 29;206(6):1297–1314. doi: 10.4049/jimmunol.2000965

FIGURE 11.

FIGURE 11.

Scheme for TLR3-activated moDCs in chronic lung disease. Initial viral replication in DCs activates TLR3 signaling that drives expansion of AT2 cells as a predominant cell source of IL-33 that acts on downstream immune cells (ILC2s and tissue macrophages) to drive IL-13 production and consequent epithelial stem cell differentiation to mucous cells for mucus production that is characteristic of chronic lung disease.